Literature DB >> 32602214

Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan.

Takashi Shida1, Natsumi Oshida2, Hideo Suzuki3, Kosuke Okada1, Takahisa Watahiki4, Sechang Oh5, Taeho Kim5, Tomonori Isobe6, Yoshikazu Okamoto7, Shun-Ichi Ariizumi8, Masakazu Yamamoto8, Junichi Shoda6.   

Abstract

AIM: The underlying mechanism of non-obese non-alcoholic fatty liver disease (NAFLD) has not been fully elucidated. We classified patients with NAFLD by sex and body mass index and compared their clinical features to clarify the background pathophysiology of non-obese NAFLD.
METHODS: A total of 404 patients with NAFLD were divided according to their body mass index (<25 [non-obese], 25 to <30 [obese], and ≥30 [severe obese]), and were further compared with 253 patients without obesity and NAFLD (non-NAFLD).
RESULTS: The proportion of the individuals with non-obese NAFLD was 25.7% in men and 27.6% in women. The male and female non-obese NAFLD groups had lower skeletal muscle mass and muscle strength than the obese NAFLD groups. The visceral fat area, although low, was ≥100 cm2 in 59.3% of men and 43.8% of women. An increase in liver fat accumulation, hepatic fibrosis, homeostasis model assessment of insulin resistance, and leptin levels was modest in the non-obese NAFLD group compared with a marked increase in the obese NAFLD groups. The muscle mass of the non-obese NAFLD group was similar to that of the non-NAFLD group, but muscle steatosis was particularly common among women. Multivariate analysis revealed that the factors contributing to increased liver fat accumulation in the non-obese NAFLD group were visceral fat area, HbA1c, myostatin, and leptin.
CONCLUSIONS: In patients with non-obese NAFLD, a sex difference was observed in the clinical features. In addition to increased visceral fat, decreased muscle mass and muscle strength, muscle atrophy (presarcopenia), and impaired glucose tolerance were considered to be important pathophysiological factors.
© 2020 The Japan Society of Hepatology.

Entities:  

Keywords:  clinical feature; muscle deterioration; non-obese NAFLD; pathophysiology; sex difference

Year:  2020        PMID: 32602214     DOI: 10.1111/hepr.13543

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

Review 1.  Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.

Authors:  Yoshihiro Kamada; Hirokazu Takahashi; Masahito Shimizu; Takumi Kawaguchi; Yoshio Sumida; Hideki Fujii; Yuya Seko; Shinya Fukunishi; Katsutoshi Tokushige; Atsushi Nakajima; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2021-10-31       Impact factor: 7.527

2.  Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.

Authors:  Tadashi Namisaki; Kosuke Kaji; Naotaka Shimozato; Daisuke Kaya; Takahiro Ozutsumi; Yuki Tsuji; Yukihisa Fujinaga; Koh Kitagawa; Masanori Furukawa; Shinya Sato; Yasuhiko Sawada; Norihisa Nishimura; Hiroaki Takaya; Yasushi Okura; Kenichiro Seki; Hideto Kawaratani; Kei Moriya; Ryuichi Noguchi; Kiyoshi Asada; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  Indian J Gastroenterol       Date:  2022-03-12

3.  Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD.

Authors:  Yoshihiro Kamada; Takashi Nakahara; Kensuke Munekage; Hideki Fujii; Yoshiyuki Sawai; Yoshinori Doi; Masafumi Ono; Hideyuki Hyogo; Yoshio Sumida; Koichi Morishita; Tatsuya Asuka; Tsunenori Ouchida; Yasuharu Imai; Eiji Miyoshi
Journal:  Hepatol Commun       Date:  2022-04-27

Review 4.  Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Shuhei Nishiguchi; Hiroko Iijima
Journal:  Int J Mol Sci       Date:  2021-02-15       Impact factor: 5.923

5.  Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity.

Authors:  Zi-Xuan Wang; Meng-Yu Wang; Rui-Xu Yang; Ze-Hua Zhao; Feng-Zhi Xin; Yu Li; Tian-Yi Ren; Jian-Gao Fan
Journal:  Front Nutr       Date:  2022-03-17

6.  Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.

Authors:  Shuhei Fukunaga; Dan Nakano; Takumi Kawaguchi; Mohammed Eslam; Akihiro Ouchi; Tsutomu Nagata; Hidefumi Kuroki; Hidemichi Kawata; Hirohiko Abe; Ryuichi Nouno; Koutaro Kawaguchi; Jacob George; Keiichi Mitsuyama; Takuji Torimura
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

7.  The Prevalence, Popular Trends, and Associated and Predictive Factors of Non-Obese Fatty Liver Disease.

Authors:  Jiang Deng; Yonghong Zhang; Limei Bu; Haitao Shi; Hailing Tang; Shenhao Wang; Qian Wang; Shuangsuo Dang; Ming Li; Zhiyi Han; Xiaolan Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-17       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.